What is Imperagen?
Imperagen operates as a sophisticated biotechnology research entity specializing in AI-driven enzyme engineering. The company distinguishes itself by integrating machine learning algorithms, quantum physics simulations, and automated laboratory workflows to design and optimize biocatalysts. This closed-loop experimentation model allows for rapid data-driven refinement, effectively reducing the time-to-market for complex industrial and life science solutions. By focusing on sustainable manufacturing and pharmaceutical synthesis, Imperagen addresses critical bottlenecks in traditional chemical production, positioning itself as a key player in the emerging bio-economy.
How much funding has Imperagen raised?
Imperagen has raised a total of $11M across 1 funding round:
Seed
$11M
Seed (2026): $11M with participation from Northern Gritstone and IQ Capital
Key Investors in Imperagen
Northern Gritstone
An investment firm founded by the Universities of Manchester, Leeds, and Sheffield, focused on supporting science and technology businesses in the North of England with a profit-with-purpose philosophy.
IQ Capital
A Cambridge and London-based venture capital firm specializing in deep-tech investments, including machine learning, AI, and advanced engineering, with a track record of global market-dominating exits.
What's next for Imperagen?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's computational infrastructure and enhancing its automated laboratory capabilities. As Imperagen scales, the primary objective will be to demonstrate the efficacy of its enzyme designs in large-scale industrial environments. The firm is expected to prioritize partnerships with major pharmaceutical and chemical manufacturers to validate its platform's utility in real-world production scenarios. Furthermore, the continued refinement of its predictive models will be essential for maintaining a competitive edge in the rapidly evolving field of synthetic biology and industrial biocatalysis.
See full Imperagen company page
